Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:05
07/16/20
07/16
09:05
07/16/20
09:05
ACIU

AC Immune

$7.20 /

+0.07 (+0.98%)

, LCI

Lannett

$5.16 /

+0.265 (+5.41%)

, DELL

Dell Technologies

$52.64 /

+0.2 (+0.38%)

, PAG

Penske Automotive

$44.69 /

+2.39 (+5.65%)

, ABT

Abbott

$96.74 /

+1.91 (+2.01%)

, BAC

Bank of America

$24.62 /

+0.485 (+2.01%)

, TWTR

Twitter

$35.68 /

+1.28 (+3.72%)

, TCDA

Tricida

$26.20 /

+0.42 (+1.63%)

, DIS

Disney

$120.91 /

+2.21 (+1.86%)

, APTO

Aptose Biosciences

$6.26 /

+0.61 (+10.80%)

, VMW

VMware

$139.57 /

+1.47 (+1.06%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

LCI Lannett
$5.16 /

+0.265 (+5.41%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

12/10/19 H.C. Wainwright
AC Immune price target raised to $11 from $8 at H.C. Wainwright
LCI Lannett
$5.16 /

+0.265 (+5.41%)

07/10/20 Raymond James
Raymond James lowers Lannett forecasts on fluphenazine competition
09/18/19 Truist
Lannett price target raised to $14 from $10 at SunTrust
08/29/19 Truist
Lannett price target raised to $10 from $7 at SunTrust
DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

07/16/20 Morgan Stanley
Morgan Stanley upgrades Dell Technologies on increasing odds of VMware spinoff
07/16/20 Morgan Stanley
Dell Technologies upgraded to Overweight from Equal Weight at Morgan Stanley
07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Daiwa
Dell Technologies initiated with a Neutral at Daiwa
PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

07/08/20 JPMorgan
Penske Automotive price target raised to $43 from $39 at JPMorgan
06/23/20 Benchmark
Benchmark upgrades Penske Automotive to Buy with shares seen at discount
06/23/20 Benchmark
Penske Automotive upgraded to Buy from Hold at Benchmark
06/10/20 Truist
Penske Automotive price target raised to $48 from $42 at SunTrust
ABT Abbott
$96.74 /

+1.91 (+2.01%)

07/14/20 Cowen
Edwards Lifesciences patent settlement removes overhang, says Cowen
07/14/20 Morgan Stanley
Edwards' removal of patent overhang a positive, says Morgan Stanley
07/13/20 Piper Sandler
Edwards Lifesciences patent settlement removes overhang, says Piper Sandler
07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
BAC Bank of America
$24.62 /

+0.485 (+2.01%)

07/09/20 DA Davidson
Bank of America downgraded to Neutral from Buy at DA Davidson
07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Seaport Global
Bank of America initiated with a Neutral at Seaport Global
07/07/20 Societe Generale
Societe Generale upgrades BofA, Citi to Buy on 'path to respectability'
TWTR Twitter
$35.68 /

+1.28 (+3.72%)

07/15/20 MKM Partners
MKM Partners raises price targets on social media stocks
07/15/20 JPMorgan
Twitter price target raised to $33 from $29 at JPMorgan
07/14/20 Wedbush
Twitter sequential audience growth could surprise positively, says Wedbush
07/10/20 Morgan Stanley
Morgan Stanley says Twitter subscription would need to be $50/year for breakeven
TCDA Tricida
$26.20 /

+0.42 (+1.63%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

07/16/20 Cowen
Disney downgraded to Market Perform from Outperform at Cowen
07/13/20
Fly Intel: Top five analyst initiations
07/13/20 Goldman Sachs
Disney initiated with a Buy at Goldman Sachs
07/10/20 JPMorgan
JPMorgan has 'increasing conviction' in Disney returning to health
APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
VMW VMware
$139.57 /

+1.47 (+1.06%)

07/07/20 Deutsche Bank
Dell offers 20%-30% upside on standalone basis, says Deutsche Bank
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20
Fly Intel: Top five analyst upgrades
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

LCI Lannett
$5.16 /

+0.265 (+5.41%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

  • 16
    Jul
  • 17
    Dec
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

PAG Penske Automotive
$44.69 /

+2.39 (+5.65%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

DIS Disney
$120.91 /

+2.21 (+1.86%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

BAC Bank of America
$24.62 /

+0.485 (+2.01%)

ACIU AC Immune
$7.20 /

+0.07 (+0.98%)

ABT Abbott
$96.74 /

+1.91 (+2.01%)

Syndicate
Aptose Biosciences 10.5M share Spot Secondary priced at $5.25 » 06:22
07/16/20
07/16
06:22
07/16/20
06:22
APTO

Aptose Biosciences

$6.26 /

+0.61 (+10.80%)

The deal range was…

The deal range was $5.25-$5.50. Piper Sandler acted as sole book running manager for the offering.

ShowHide Related Items >><<
APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

  • 16
    Jul
  • 17
    Dec
APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

On The Fly
Fly Intel: After-Hours Movers » 19:05
07/15/20
07/15
19:05
07/15/20
19:05
AA

Alcoa

$12.68 /

+0.07 (+0.56%)

, PIXY

ShiftPixy

$4.72 /

+0.08 (+1.72%)

, HIG

Hartford Financial

$40.41 /

+1.68 (+4.34%)

, NBRV

Nabriva Therapeutics

$0.66 /

+0.0338 (+5.36%)

, RTIX

RTI Surgical

$3.80 /

+0.41 (+12.11%)

, DELL

Dell Technologies

$52.64 /

+0.2 (+0.38%)

, VMW

VMware

$139.57 /

+1.47 (+1.06%)

, SPCE

Virgin Galactic

$18.55 /

+0.105 (+0.57%)

, MNK

Mallinckrodt

$3.10 /

+0.365 (+13.37%)

, DKNG

DraftKings

$32.55 /

+2.31 (+7.64%)

, SNBR

Sleep Number

$53.63 /

+1.84 (+3.55%)

, TCDA

Tricida

$26.20 /

+0.42 (+1.63%)

, APTO

Aptose Biosciences

$6.26 /

+0.61 (+10.80%)

, CYTK

Cytokinetics

$28.98 /

+1.1 (+3.95%)

, BCEL

Atreca

$18.44 /

+0.24 (+1.32%)

, TWTR

Twitter

$35.68 /

+1.28 (+3.72%)

, FEYE

FireEye

$12.36 /

+0.53 (+4.48%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

RTIX RTI Surgical
$3.80 /

+0.41 (+12.11%)

PIXY ShiftPixy
$4.72 /

+0.08 (+1.72%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

BCEL Atreca
$18.44 /

+0.24 (+1.32%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
04/23/20 JPMorgan
Alcoa price target lowered to $12 from $14 at JPMorgan
PIXY ShiftPixy
$4.72 /

+0.08 (+1.72%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

05/05/20 Deutsche Bank
Hartford Financial price target lowered to $53 from $63 at Deutsche Bank
04/14/20 Morgan Stanley
Hartford Financial upgraded to Overweight from Equal Weight at Morgan Stanley
04/08/20 RBC Capital
Hartford Financial price target lowered to $39 from $66 at RBC Capital
04/01/20 Wells Fargo
Hartford Financial upgraded to Overweight from Equal Weight at Wells Fargo
NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
RTIX RTI Surgical
$3.80 /

+0.41 (+12.11%)

06/16/20 Cantor Fitzgerald
RTI Surgical assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
RTI Surgical assumed with an Overweight at Cantor Fitzgerald
01/17/20 Cantor Fitzgerald
RTI Surgical price target raised to $6 from $4 at Cantor Fitzgerald
09/16/19 Sidoti
RTI Surgical initiated with a Buy at Sidoti
DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

07/09/20
Fly Intel: Top five analyst initiations
07/09/20 Daiwa
Dell Technologies initiated with a Neutral at Daiwa
07/07/20 Deutsche Bank
Dell offers 20%-30% upside on standalone basis, says Deutsche Bank
06/30/20 Cowen
Dell Technologies initiated with a Market Perform at Cowen
VMW VMware
$139.57 /

+1.47 (+1.06%)

06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 Wells Fargo
Dell Technologies price target raised to $70 from $57 at Wells Fargo
SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

07/13/20 Alembic Global
Virgin Galactic initiated with an Overweight at Alembic Global
03/24/20 Morgan Stanley
Morgan Stanley upgrades Virgin Galactic to Overweight after over 70% drop
03/24/20 Morgan Stanley
Virgin Galactic upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/20 Morgan Stanley
Lead up to next lunar landings can have 'powerful impact,' says Morgan Stanley
MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

07/15/20 Rosenblatt
DraftKings recent pullback a buying opportunity, says Rosenblatt
07/14/20 Craig-Hallum
NJ sports betting up despite no sports, iGaming also strong, says Craig-Hallum
07/14/20 Stephens
Stephens more confident in DraftKings position after NJ iGaming data
07/08/20 Jefferies
GVC has 'credible' U.S. sports betting aspirations, says Jefferies
SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

07/10/20
Fly Intel: Top five analyst upgrades
07/10/20 Piper Sandler
Piper Sandler upgrades Sleep Number on 'robust' mattress demand
07/09/20 Piper Sandler
Sleep Number upgraded to Overweight from Neutral at Piper Sandler
03/25/20 Raymond James
Sleep Number downgraded to Market Perform on weak traffic at Raymond James
TCDA Tricida
$26.20 /

+0.42 (+1.63%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

07/15/20 Cantor Fitzgerald
Cytokinetics price target raised to $41 from $29 at Cantor Fitzgerald
07/15/20 JMP Securities
Cytokinetics price target raised to $29 from $23 at JMP Securities
07/14/20 H.C. Wainwright
Cytokinetics price target raised to $38 from $35 at H.C. Wainwright
07/14/20 Piper Sandler
Cytokinetics price target raised to $33 from $28 at Piper Sandler
BCEL Atreca
$18.44 /

+0.24 (+1.32%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
07/01/20 Canaccord
Atreca price target raised to $33 from $23 at Canaccord
06/10/20 H.C. Wainwright
H.C. Wainwright says Genmab/AbbVie pact a 'big win' for companies like Atreca
04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
TWTR Twitter
$35.68 /

+1.28 (+3.72%)

07/15/20 MKM Partners
MKM Partners raises price targets on social media stocks
07/15/20 JPMorgan
Twitter price target raised to $33 from $29 at JPMorgan
07/14/20 Wedbush
Twitter sequential audience growth could surprise positively, says Wedbush
07/10/20 Morgan Stanley
Morgan Stanley says Twitter subscription would need to be $50/year for breakeven
FEYE FireEye
$12.36 /

+0.53 (+4.48%)

04/13/20 BMO Capital
FireEye price target lowered to $12.50 from $17 at BMO Capital
03/05/20
Fly Intel: Top five analyst upgrades
03/05/20 Goldman Sachs
Goldman upgrades FireEye to Buy, sees 33% upside in the shares
03/05/20 Goldman Sachs
FireEye upgraded to Buy from Neutral at Goldman Sachs
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

TCDA Tricida
$26.20 /

+0.42 (+1.63%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

RTIX RTI Surgical
$3.80 /

+0.41 (+12.11%)

PIXY ShiftPixy
$4.72 /

+0.08 (+1.72%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

BCEL Atreca
$18.44 /

+0.24 (+1.32%)

APTO Aptose Biosciences
$6.26 /

+0.61 (+10.80%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

  • 16
    Jul
  • 16
    Jul
  • 17
    Jul
  • 19
    Jun
  • 03
    Jun
  • 20
    May
  • 17
    Dec
VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

CYTK Cytokinetics
$28.98 /

+1.1 (+3.95%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

VMW VMware
$139.57 /

+1.47 (+1.06%)

TWTR Twitter
$35.68 /

+1.28 (+3.72%)

SPCE Virgin Galactic
$18.55 /

+0.105 (+0.57%)

SNBR Sleep Number
$53.63 /

+1.84 (+3.55%)

NBRV Nabriva Therapeutics
$0.66 /

+0.0338 (+5.36%)

MNK Mallinckrodt
$3.10 /

+0.365 (+13.37%)

HIG Hartford Financial
$40.41 /

+1.68 (+4.34%)

FEYE FireEye
$12.36 /

+0.53 (+4.48%)

DKNG DraftKings
$32.55 /

+2.31 (+7.64%)

DELL Dell Technologies
$52.64 /

+0.2 (+0.38%)

AA Alcoa
$12.68 /

+0.07 (+0.56%)

Syndicate
Aptose Biosciences announces offering of common shares, no amount given » 16:03
07/15/20
07/15
16:03
07/15/20
16:03
APTO

Aptose Biosciences

$6.32 /

+0.67 (+11.86%)

Aptose Biosciences…

Aptose Biosciences announced that it has commenced an underwritten public offering of its common shares. Aptose intends to use the net proceeds of the offering to (i) accelerate and expand clinical trials for CG-806; (ii) accelerate and expand clinical trials for APTO-253; (iii) acquire and fund (including through partnerships and in-licensing) additional clinical assets; and (iv) for working capital and general corporate purposes. Piper Sandler is acting as the sole active book-running manager for the offering.

ShowHide Related Items >><<
APTO Aptose Biosciences
$6.32 /

+0.67 (+11.86%)

APTO Aptose Biosciences
$6.32 /

+0.67 (+11.86%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
APTO Aptose Biosciences
$6.32 /

+0.67 (+11.86%)

  • 17
    Dec
Over a month ago
Hot Stocks
Aptose receives FDA allowance of IND for Phase 1a/b study of CG-806 » 07:04
06/29/20
06/29
07:04
06/29/20
07:04
APTO

Aptose Biosciences

$6.29 /

-0.36 (-5.41%)

Aptose Biosciences…

Aptose Biosciences announced that the U.S. Food and Drug Administration completed its review of the company's Investigational New Drug application and has granted IND allowance for the initiation of a Phase 1a/b clinical study of CG-806, the company's highly potent, oral FLT3/BTK inhibitor, in patients with acute myeloid leukemia. CG-806 is currently in a Phase 1 dose escalation study in patients with B-cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin's lymphomas, who have failed or are intolerant to current therapies. Aptose intends to initiate the Phase 1 a/b study in the second half of 2020 in AML patients who have relapsed, are resistant or refractory to current treatment.

ShowHide Related Items >><<
APTO Aptose Biosciences
$6.29 /

-0.36 (-5.41%)

APTO Aptose Biosciences
$6.29 /

-0.36 (-5.41%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
APTO Aptose Biosciences
$6.29 /

-0.36 (-5.41%)

  • 17
    Dec
Recommendations
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler » 13:25
06/12/20
06/12
13:25
06/12/20
13:25
APTO

Aptose Biosciences

$6.72 /

+0.05 (+0.75%)

Following an update made…

Following an update made in conjunction with the the Congress of the European Hematology Association, or EHA, meeting, Piper Sandler analyst Tyler Van Buren said the Phase I dose escalation trial for 806 "continues to progress well." An "added surprise" reported by Aptose Biosciences was that lymphocytosis was observed early in a DL4 CLL/SLL patient, which "continues to suggest that 806 is reaching therapeutically-active levels in patients," according to Van Buren. The analyst, who said he continues to "like the setup into ASH," reiterates an Overweight rating on Aptose shares following what he called an "incrementally positive" update.

ShowHide Related Items >><<
APTO Aptose Biosciences
$6.72 /

+0.05 (+0.75%)

APTO Aptose Biosciences
$6.72 /

+0.05 (+0.75%)

06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/06/20 H.C. Wainwright
Aptose Biosciences price target raised to $9 from $6 at H.C. Wainwright
APTO Aptose Biosciences
$6.72 /

+0.05 (+0.75%)

Recommendations
JonesTrading optimistic about potential of Aptose Biosciences' CG-806 » 11:00
06/12/20
06/12
11:00
06/12/20
11:00
APTO

Aptose Biosciences

$6.87 /

+0.2 (+3.00%)

JonesTrading analyst…

JonesTrading analyst Matthew Cross keeps a Buy rating and $12 price target on Aptose Biosciences amid the company's key update on the Phase 1 dose-escalation study of CG-806 in patients with r/r B-cell malignancies at the EHA virtual conference. While the analyst noted that this is still preliminary at this stage, he said he is "increasingly optimistic" about the potential of CG-806.

ShowHide Related Items >><<
APTO Aptose Biosciences
$6.87 /

+0.2 (+3.00%)

APTO Aptose Biosciences
$6.87 /

+0.2 (+3.00%)

02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/06/20 H.C. Wainwright
Aptose Biosciences price target raised to $9 from $6 at H.C. Wainwright
01/09/20 Piper Sandler
Aptose Biosciences initiated with an Overweight at Piper Sandler
APTO Aptose Biosciences
$6.87 /

+0.2 (+3.00%)

Hot Stocks
Aptose Biosciences presents early Phase 1a/b CG-806 clinical findings » 07:03
06/12/20
06/12
07:03
06/12/20
07:03
APTO

Aptose Biosciences

$6.67 /

-0.25 (-3.61%)

Aptose Biosciences…

Aptose Biosciences announced that new clinical data on CG-806, its oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, was presented in a poster presentation today at the 25th Congress of the European Hematology Association, EHA25 Virtual Congress. Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas reviewed CG-806 data for eight patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma or non-Hodgkin's lymphoma in the first in-human Phase 1 a/b, open-label, single arm, multicenter dose-escalation clinical study. The poster is available on the posters and presentations section of the Aptose website here. For more information on the ongoing study, please visit www.clinicaltrials.gov here. CG-806 was well-tolerated in patients treated at 150mg, 300mg and 450mg BID over multiple cycles, with no drug-related dose-limiting toxicities or serious adverse events. CG-806 treatment led to lymphocytosis in two CLL patients and delivered complete inhibition of phospho-BTK and multiple oncogenic survival pathways in all patients receiving greater than or equal to 300mg BID. Plasma from CG-806 treated patients completely inhibited phospho-FLT3 in a plasma inhibitory activity assay, and patients receiving greater than or equal to 300mg BID achieved steady state PK levels known to be effective in murine tumor models. Separately, Aptose announced it has submitted an IND for a parallel Phase 1 a/b clinical study of CG-806 in patients with relapsed or refractory FLT3-mutant or FLT3-wildtype acute myeloid leukemia.

ShowHide Related Items >><<
APTO Aptose Biosciences
$6.67 /

-0.25 (-3.61%)

APTO Aptose Biosciences
$6.67 /

-0.25 (-3.61%)

02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/06/20 H.C. Wainwright
Aptose Biosciences price target raised to $9 from $6 at H.C. Wainwright
01/09/20 Piper Sandler
Aptose Biosciences initiated with an Overweight at Piper Sandler
APTO Aptose Biosciences
$6.67 /

-0.25 (-3.61%)

Earnings
Aptose Biosciences reports Q1 EPS (15c), consensus (15c) » 16:04
05/05/20
05/05
16:04
05/05/20
16:04
APTO

Aptose Biosciences

$7.07 /

+0.255 (+3.74%)

Total cash and cash…

Total cash and cash equivalents and investments as of March 31, were $90M. Based on current operations, the company expects that cash on hand and available capital provide the company with sufficient resources to fund all planned company operations including research and development into 2022."I'm pleased to report that Aptose has made significant progress thus far in 2020. Despite external turmoil caused by the COVID-19 pandemic, we've continued to advance our two clinical programs, CG-806 and APTO-253, and continued dose escalation," said William G. Rice, chairman, president and CEO. "Both drug candidates continue to demonstrate favorable safety profiles to date, and have generated proof of pharmacologic activity and early indications of clinical activity. CG-806 has, thus far, materialized as resilient to the COVID-19 disruptions because of its profile as a safe, orally administered agent directed at critically ill patients with hematologic malignancies and because of the sites chosen for our clinical studies. We look forward to reporting our progress on both clinical fronts at major hematology conferences throughout the remainder of the year."

ShowHide Related Items >><<
APTO Aptose Biosciences
$7.07 /

+0.255 (+3.74%)

02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/06/20 H.C. Wainwright
Aptose Biosciences price target raised to $9 from $6 at H.C. Wainwright
01/09/20 Piper Sandler
Aptose Biosciences initiated with an Overweight at Piper Sandler
Over a quarter ago
Hot Stocks
Aptose Biosciences presents preliminary data on CG-806 » 09:07
04/27/20
04/27
09:07
04/27/20
09:07
APTO

Aptose Biosciences

$8.22 /

+0.08 (+0.98%)

Aptose Biosciences…

Aptose Biosciences presented the early clinical data on CG-806, the company's oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, at the AACR Virtual Annual Meeting I, in lieu of the live oral presentation originally planned. Rafael Bejar M.D., Ph.D., Aptose's Chief Medical Officer, presented a video summary of Abstract # 9967 - Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphomas. The first-in-human tests of CG-806 are being carried out in a Phase 1a/b clinical study. The target population in the study includes patients with significant unmet needs including patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic leukemia or non-Hodgkin lymphoma (NHL) who have failed or been intolerant to two lines of established therapy. CG-806 is administered as oral capsules dosed twice daily in 28-day cycles. The study design includes an accelerated titration followed by a 3+3 dose escalation to establish the recommended Phase 2 dose for planned expansion cohorts and future studies. The first patient, treated with 150 mg BID of CG-806, was heavily pretreated, carried a TP53 mutation, and had severe thrombocytopenia prior to study entry. This patient currently is in the eleventh cycle of therapy without having experienced a dose-limiting toxicity and has been dose escalated to the 450 mg BID dose level. The second patient, treated at the 300 mg BID dose level, had significant marrow involvement with neutropenia and thrombocytopenia at study entry, and developed a brisk lymphocytosis, but did not experience a DLT through four cycles of therapy including no worsening of their thrombocytopenia or neutropenia. The study has now completed three dose levels without observing any drug-related severe adverse events and has not reached a dose-limiting toxicity. Three patients completed the safety evaluation period at the third dose level, 450 mg BID, and as a result, the fourth dose level was opened. The first patient, previously dosed at 150 mg BID was dose escalated to dose level 3 at 450 mg BID. Enrollment is open and dosing is ongoing at the 600 mg BID dose level with no drug-related SAEs or DLTs encountered to date. Key findings to date: No drug-related SAEs or DLTs have been observed in patients to date. CG-806 demonstrates favorable steady state pharmacokinetics evidenced by stable trough plasma concentrations reached by Day 8 in the first two patients treated at dose levels 1 and 2. CG-806 has shown on-target pharmacologic activity demonstrated by plasma inhibitory assays with reporter cells exposed to patient plasma for 6 hours. Phospho-BTK is markedly reduced after exposure to plasma from the patient treated at dose level 1 and completely abrogated with plasma form the patient treated at dose level 2. Similar results are seen for the phosphorylation of PDGFR-alpha, a target of CG-806, for SYK, which lies in the same signaling pathway as BTK and for ERK. Lymphocytosis was noted at dose level 2 - pharmacologic BTK inhibition in CLL promotes exfiltration.

ShowHide Related Items >><<
APTO Aptose Biosciences
$8.22 /

+0.08 (+0.98%)

02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/06/20 H.C. Wainwright
Aptose Biosciences price target raised to $9 from $6 at H.C. Wainwright
01/09/20 Piper Sandler
Aptose Biosciences initiated with an Overweight at Piper Sandler

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.